Brought to you by 
Mologen offers lefitolimod rights to iPharma; definitive agreement not reached
21 Jun 2022
Executive Summary
Mologen AG and iPharma Ltd. signed a binding term sheet that could culminate with iPharma gaining exclusive rights to develop and sell Mologen’s Phase III oncology project lefitolimod (MGN1703) in China, Hong Kong, Macau, Taiwan, and Singapore.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mologen offers lefitolimod rights to iPharma; definitive agreement not reached
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice